MEPs Demand Scrutiny of EU–Philip Morris Interactions
Five members of the European Parliament’s Health Committee have demanded that the European Commission answer questions regarding its interactions with Philip Morris International (PMI). Investigation documents reveal that PMI discussed overseas market barriers for its tobacco and nicotine products with EU trade officials. And the EU subsequently took action at least three times that could have benefited PMI.
Key Points at a Glance
- Five members of the European Parliament’s Health Committee have requested that. The European Commission appears for questioning regarding its interactions with PMI.
- The investigation revealed numerous meetings between EU trade officials and tobacco lobbyists.
- Documents show that PMI discussed overseas market barriers with trade officials, and the EU subsequently took action at least three times that could have benefited PMI.
- The EU has signed a WHO treaty requiring interactions with the tobacco industry to be limited to what is “strictly necessary,” and that meetings be transparent; not all meetings were disclosed through regular channels.
- The European Commission plans to advance revisions to the Tobacco Products Directive this year to address vapes, a process expected to face intense lobbying.
Investigation Raises Concerns Over Tobacco Lobbying
January 15, 2026. According to POLITICO. Some members of the European Parliament are demanding that the European Commission explain its interactions with Philip Morris International (PMI). An investigation by POLITICO and The Examination claims that there are numerous records of meetings between EU trade officials and tobacco lobbyists. Raising concerns about compliance with global rules on tobacco lobbying.
Health Committee Seeks Commission Testimony
Five members of the European Parliament’s Health Committee confirmed to POLITICO that they want to invite the European Commission to appear and answer questions. Citing concerns that the Commission may have violated global rules on tobacco lobbying.
Documents Detail PMI Engagement With EU Trade Officials
The report cites documents showing that PMI discussed barriers to its tobacco and nicotine products in overseas markets with EU trade officials. Subsequently, EU trade officials took action at least three times that could have benefited the company. In one email, PMI thanked EU trade officials, stating that they had provided “great help.”
WHO Treaty and Transparency Requirements
The report notes that the EU has signed a World Health Organization (WHO) treaty requiring governments to limit interactions with the tobacco industry to what is “strictly necessary” for regulation and that such meetings be transparent. The investigation also states that not all meetings were disclosed through the European Commission’s regular channels.
Tobacco Directive Revisions Expected to Draw Lobbying Pressure
As the European Commission seeks to re-establish its global leadership in tobacco control. The report notes that the EU plans to advance revisions to the Tobacco Products Directive this year to address vapes. This process is expected to attract intense lobbying from industry stakeholders.
MEPs Warn of Commercial Interests Over Public Health
Social Democrat (S&D) MEP Romana Jerković stated. “We live in an era where commercial interests are triumphing over public health objectives,” adding that a clear line must be drawn between public policy and tobacco lobbying. She said the tobacco industry has long used lobbying to delay and weaken regulations, calling it a “deliberate strategy.”
Lawmakers Behind the Parliamentary Request
The initial request for the European Commission to answer questions in Parliament came from Nicolás González Casares (S&D). He also submitted written questions. The proposal was supported by Tiemo Wölken (S&D). Tilly Metz (Greens) and Stine Bosse (Renew).
European Commission Responds to Allegations
A European Commission spokesperson stated that the EU executive body “strictly adheres” to the WHO Framework Convention on Tobacco Control and that it “does not develop, influence, or lobby for specific health policies in third countries on behalf of any industry.”
